Indonesia court finds drugmakers at fault over toxic cough syrup, awards parents
Adds comment from family lawyer in paragraph 9-10
By Stanley Widianto
JAKARTA, Aug 23 (Reuters) -An Indonesian court ordered two local companies to pay up to 60 million rupiah ($3,850) to each family whose children died of an acute kidney injury or were seriously injured after consuming toxic cough syrup.
More than 200 children in Indonesia died of the injury and about 120 more survived, some of whom lived with disabilities which led to financial hardships for their parents.
Indonesian courts have cited lax oversight by pharmaceutical companies, including local drugmakers and some suppliers, as well as the country's food and drugs agency (BPOM), in hearings into the poisonings.
In late 2022, more than 20 families launched a civil suit against the agency, the health ministry, and several companies.
Judges at the Central Jakarta court found a drugmaker and a supplier, Afi Farma and CV Samudera Chemical, at fault in the poisonings, according to a ruling released late on Thursday.
The health ministry and the BPOM were cleared of wrongdoing.
The court ordered the companies to pay the parents who brought the suit compensation of 50 million rupiah for children who died and 60 million rupiah for children who were injured.
Parents had asked for 3.4 billion rupiah for each child that died, and 2.2 billion rupiah for survivors. Indonesia's 2023 gross domestic product per capita was nearly $5,000, data from the country's Statistics Bureau shows.
Siti Habiba, the lawyer for the parents, said the families were disappointed by the ruling, as the money was given "as though we were beggars."
"This breaks a lot of the victims' hearts," she said, adding the court ignored the parents' government oversight concerns by not finding the health ministry and the BPOM at fault.
The court document, posted on its website, did not include reasons for the decision.
Afi Farma's lawyer Reza Wendra Prayogo told Reuters on Friday the firm was "disappointed" with the civil case ruling and the company was still considering its next legal step.
Last year, a criminal court found East Java-based drugmaker Afi Farma guilty of negligence and jailed officials for not testing the ingredients sent by its supplier.
The syrups contained ethylene glycol (EG), a commonly used chemical in products such as brake fluid and antifreeze. A court document from that criminal case said the EG concentration in the syrups reached as high as 99%, where international standards say only 0.1% of EG is safe for consumption.
The company has repeatedly denied negligence.
Reuters could not immediately contact CV Samudera Chemical, an Indonesian soapmaker, whose toxic ingredient made its way to Afi Farma, according to the court document of the Afi Farma criminal case in 2023.
The World Health Organization said the contaminated medicines had also killed children in Gambia and Uzbekistan in 2022.
($1 = 15,595 rupiah)
Reporting by Stanley Widianto; Editing by Michael Perry and Stephen Coates
Ultime news
Disclaimer: le entità di XM Group forniscono servizi di sola esecuzione e accesso al nostro servizio di trading online, che permette all'individuo di visualizzare e/o utilizzare i contenuti disponibili sul sito o attraverso di esso; non ha il proposito di modificare o espandere le proprie funzioni, né le modifica o espande. L'accesso e l'utilizzo sono sempre soggetti a: (i) Termini e condizioni; (ii) Avvertenza sui rischi e (iii) Disclaimer completo. Tali contenuti sono perciò forniti a scopo puramente informativo. Nello specifico, ti preghiamo di considerare che i contenuti del nostro servizio di trading online non rappresentano un sollecito né un'offerta ad operare sui mercati finanziari. Il trading su qualsiasi mercato finanziario comporta un notevole livello di rischio per il tuo capitale.
Tutto il materiale pubblicato sul nostro servizio di trading online è unicamente a scopo educativo e informativo, e non contiene (e non dovrebbe essere considerato come contenente) consigli e raccomandazioni di carattere finanziario, di trading o fiscale, né informazioni riguardanti i nostri prezzi di trading, offerte o solleciti riguardanti transazioni che possano coinvolgere strumenti finanziari, oppure promozioni finanziarie da te non richieste.
Tutti i contenuti di terze parti, oltre ai contenuti offerti da XM, siano essi opinioni, news, ricerca, analisi, prezzi, altre informazioni o link a siti di terzi presenti su questo sito, sono forniti "così com'è", e vanno considerati come commenti generali sui mercati; per questo motivo, non possono essere visti come consigli di investimento. Dato che tutti i contenuti sono intesi come ricerche di investimento, devi considerare e accettare che non sono stati preparati né creati seguendo i requisiti normativi pensati per promuovere l'indipendenza delle ricerche di investimento; per questo motivo, questi contenuti devono essere considerati come comunicazioni di marketing in base alle leggi e normative vigenti. Assicurati di avere letto e compreso pienamente la nostra Notifica sulla ricerca di investimento non indipendente e la nostra Informativa sul rischio riguardante le informazioni sopra citate; tali documenti sono consultabili qui.